PD
Therapeutic Areas
Elicio Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ELI-002 2P | KRAS-mutated Pancreatic Ductal Adenocarcinoma (PDAC) & Colorectal Cancer (CRC) - Adjuvant/MRD setting | Phase 2 |
| ELI-002 7P | Solid tumors with KRAS mutations | Phase 1 |
| Drug | Indication | Phase |
|---|---|---|
| ELI-002 2P | KRAS-mutated Pancreatic Ductal Adenocarcinoma (PDAC) & Colorectal Cancer (CRC) - Adjuvant/MRD setting | Phase 2 |
| ELI-002 7P | Solid tumors with KRAS mutations | Phase 1 |